Company Description
CardieX is a commercial-stage digital healthcare company using our medical devices to redefine the way hypertension, cardiovascular disease (CVD), and other major vascular diseases are clinically diagnosed and managed.
Our SphygmoCor XCEL is a vital signs and vascular biometric monitoring device that offers non-invasive assessment of the central aortic pressure waveform, including both pressures and indices of arterial stiffness, providing noninvasive measurement of arterial pressure that the heart, brain, and kidneys actually experience.
Our two subsidiaries, ATCOR Medical and CONNEQT Health, are focused on separate, but complementary, sectors of our target healthcare market.
ATCOR pioneered the SphygmoCor technology and continues to focus on servicing specialist health care providers, on-site clinical trials, research programs, and hospital networks with a variety of proprietary vascular biomarker solutions.
Launched in 2021, the CONNEQT business is introducing a suite of new devices and digital solutions strategically targeted to consumer health, general health care providers, remote patient monitoring, decentralized clinical trials, and home health.
| Country | Australia |
| Founded | 1994 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Craig R. Cooper |
Contact Details
Address: 55 Lime Street, Suite 301 Sydney, NSW 2000 Australia | |
| Phone | +61 2 9874 8761 |
| Website | cardiex.com |
Stock Details
| Ticker Symbol | CDEX |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001951005 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Cooper, BEc., LLB (Hons) | Chief Executive Officer & Director |
| Niall Cairns, BEc., CA ANZ, FAICD | Executive Chairman & Director |
| Jarrod White | Director, Interim Chief Financial Officer |
| R. King Nelson, BA, MBA | Director |
| Lesa Musatto | Director |
| Steven Kesten, M.D. | Chief Medical Officer |
| Mark Gorelick, Ph.D. | Chief Product Officer |
| Ahmad Qasem, Ph.D. | Chief Science & Research Officer |
| Catherine Liao | Chief Strategy Officer |
| Josh Stevens | President, CONNEQT |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 26, 2023 | RW | Filing |
| Sep 19, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Sep 13, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Sep 8, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Sep 5, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Aug 30, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Aug 30, 2023 | F-6 | Filing |
| Jul 25, 2023 | F-1 | Registration statement for certain foreign private issuers |
| Jun 26, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 23, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |